“Incompetence, racism and prejudice delayed my diagnosis”
Women and Parkinson's
Author: Manon DayPublished: 23 January 2020
Prep: Cook: Serves:
It took a decade for Manon Day to be diagnosed with
Parkinson’s – with clinicians treating her as though she was a drug addict,
causing her to feel “mistreated” and “powerless”. She explains the role being a
young black woman played in her delayed diagnosis – and why “we need more
awareness to break the myths and stereotypes” around who the condition affects
My Parkinson’s symptoms started at the age of 17, but it
wasn’t until 10 years later that I was diagnosed with the condition, aged 27.
Over the years, I was living with uncertainty and was
worried about my physical state. At first, I struggled with low blood pressure
and I was fainting several times a week. Now, my symptoms include stiffness,
difficulty moving, speech problems, bladder dysfunction, fatigue and more.
When I was officially diagnosed with Parkinson’s in 2011,
I was overwhelmed and in shock – it had taken a decade to get the right
diagnosis. I knew for sure that Parkinson’s was going to change everything.
Women are less likely to be diagnosed with Parkinson’s
compared to men. Being a young black woman played a huge role in my delayed
diagnosis. The neurologists I initially consulted stigmatised me. They didn’t
believe me when I explained my symptoms: they thought I was a drug addict. I
was mistreated and my experience was horrible. It reached the point where I
became very ill and could not walk because my body was so stiff. Racism was the
cause of my delayed diagnosis and I felt powerless.
Due to incompetence and prejudice, I did not receive the
medical care that I so desperately needed. Every time the paramedics rushed me
to the hospital emergency room, the neurologists sent me back home right away.
Consequently, I felt distressed and abandoned by the healthcare system.
I changed hospitals and thankfully, as of now, I receive the best medical care and treatment at the Montreal Neurological Institute and Hospital. I have had an excellent response to levodopa and through medication, diet and exercise, I’m managing my Parkinson’s.
“It’s a devastating diagnosis to receive in the
prime of your life”
When I told my family about my diagnosis, they were stunned, as we thought that the condition usually afflicts the elderly. We started researching it intensely. Although my movement disorder specialist gave me lots of information about Parkinson’s, I had no knowledge about how the condition affects women in general – for example how I experience more symptoms of rigidity and slowness during my periods.
There were several challenges related to my young onset
diagnosis: I couldn’t pursue my studies in the field of translation, and I
chose not to conceive children because pregnancy is a risk to my health. In
addition to my Parkinson’s, I live with a second rare disease called acromegaly,
which I was diagnosed with in 2014. It’s a hormonal disorder that affects
approximately 2,000 people in Canada. It’s a damaging and incurable disease and,
as far as I know, I am the only person in the world living with both young
onset Parkinson’s and acromegaly.
Parkinson’s has also had negative effects on my hobbies and social life – it’s a devastating diagnosis to receive in the prime of your life when you are full of plans for the future.
“Parkinson’s doesn’t only affect old Caucasian
Generally speaking, women and people from minority backgrounds are underrepresented in the Parkinson’s research community. I am registered in a clinical Parkinson’s trial database called the Quebec Parkinson’s Network because I want to be involved and share my experience to advance knowledge in the scientific community. I think playing a small role can have a positive impact in the development of future therapies.
I’ve never met other black men or women with Parkinson’s in Montreal – and while I’m in contact with a few people online, I don’t know the details of their personal stories. It’s a sad reality that minorities face several challenges to get diagnosed correctly with Parkinson’s. That’s why three years ago I created a Facebook group called Everything about Parkinson’s Disease to connect with fellow patients, young or old – and of different races. It now has over 9,000 members worldwide. Running the group gives me a sense of purpose and I’m very happy to make a difference in people’s lives.
We need more awareness to break the myths and stereotypes around the condition. Parkinson’s doesn’t only affect old Caucasian men. It can impact anyone, regardless of age or ethnicity.
Need to know: Manon Day is 35 years old and lives in Montreal, Canada. She was diagnosed with Parkinson’s in 2011, age 27, and subsequently quit her studies in translation. She is now a Parkinson’s campaigner and runs a Facebook group called Everything about Parkinson’s Disease to raise awareness of the condition and how it can affect people of all backgrounds.
The facts: who does Parkinson’s affect?
Parkinson’s affects people of all racial and ethnic backgrounds and cultures
Around 10 million people across the globe live with the condition – and by 2040, it is estimated that there will be 13 million people with Parkinson’s
Our ‘In My Country’ series features interviewees from organisations around the world to spotlight the differing experiences of and attitudes towards people with Parkinson’s globally
Women and Parkinson’s: Our campaign
It is estimated that three million women worldwide are living with Parkinson’s – yet their specific needs and experiences are often ignored, leading to disparities in diagnosis, treatment and medication. Each week, we’ll be sharing the little-heard stories of women with the condition to find out how their lives are being affected by a shocking data gap when it comes to women and Parkinson’s. This is just the start.
We want to raise awareness of women’s experience of the condition within the medical profession, so that women’s symptoms are taken seriously.
We think more research is needed into the impact of Parkinson’s on women, so that they can benefit from tailored medication and treatment.
We want to explore ways to offer better support for those women managing the condition alongside caring responsibilities.
Join us – #WomenAndParkinsons.
For more information on women and Parkinson’s please visit the EPDA website.
If you have a story to tell about being a woman with Parkinson’s – or some information about the impact of the condition on women for us to share with the global Parkinson’s community – please get in touch.
Meet EPDA vice-president Susanna Lindvall as she gets involved in #UniteForParkinsons 2018
International Women's Day interview special
4 days ago
New biotech to drive forward GDNF treatment for Parkinson’s disease
UK charity Parkinson’s UK is creating a new company, Vivifi Biotech, to develop a treatment with potential to stop or reverse Parkinson’s disease. The experimental therapy surgically distributes GDNF, a protein that is naturally produced by the brain to protect cells, directly into the brain. The charity previously funded a clinical trial to investigate whether boosting GDNF levels could regenerate dying brain cells in people with Parkinson’s. Over the next two years, it will invest up to £800,000 to prepare for a second trial. Arthur Roach, head of research at Parkinson’s UK, said: “While our initial trial didn’t meet its critical endpoint, it did reveal robust evidence indicating that GDNF can possibly reverse Parkinson’s. This is why Parkinson’s UK is committed to continuing research into this potential treatment.” Vivifi Biotech, Roach added, will “bring the right people together to plan a new trial that meets the needs of patients, regulatory…
New wearable medical device for Parkinson’s disease to launch this year
The Imperial College London Innovation Fund, UK, has invested £205,000 to support UK-based tech company Charco Neurotech in its development of a non-invasive medical device for people with Parkinson’s disease. CUE1, a circular device that attaches to the sternum with medical adhesives, uses specialised vibration to help alleviate physical symptoms of Parkinson’s disease. Initial user testing among people with the condition found that the device improved movement by an average of 16%, with testers reporting benefits for walking and fine motor tasks. Lucy Jung, CEO and co-founder of Charco Neurotech, said: “We believe that CUE1 has the potential to significantly improve [Parkinson’s disease] symptoms through its unique controlled vibration technology. We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials.” Charco Neurotech will use the Imperial College investment to initiate a clinical trial and fund the device’s manufacture for…
New study brings scientists a “vital step” closer to understanding Parkinson’s disease
A new study from scientists at the University of Cambridge, UK, has brought researchers “a vital step” closer to discovering the origins of Parkinson’s disease. The research, published in the scientific journal ‘Nature Communications’, offered insights on the protein alpha-synuclein, which clumps together in the neurons of people with Parkinson’s. The study focused on how the protein functions in those without the condition and revealed that it sticks to the inner side of the plasma membrane of nerve cells, but not the outer membrane – an insight that could help in the search for a cure. Lead study author, Dr Giuliana Fusco, said: “This study could unlock more information about this debilitating neurodegenerative disorder that can leave people unable to walk and talk. If we want to cure Parkinson’s, first we need to understand the function of alpha-synuclein, a protein present in everyone’s brains.”